Stem Cell Therapy Research: Creative Biolabs Advances iPSC-Derived Macrophage Solutions

By: Get News
Creative Biolabs advances disease research by developing and promoting macrophages derived from induced pluripotent stem cells (iPSCs), a promising tool for studying macrophages.

New York, USA - September 20, 2024 - The potential of stem cell therapy in medical research and clinical applications is increasingly evident, particularly in the treatment of cancer, genetic disorders, and immune-related conditions. As a globally leading provider of innovative biotechnological services, Creative Biolabs is at the forefront of this field.

"iPSCs, with their pluripotent capabilities, can differentiate into various cell types, including immune cells like macrophages. Macrophages are crucial in modulating immune responses and facilitating tissue repair," stated an expert from Creative Biolabs' iPSC research team.

In response to the increasing demand for stem cell research and immunotherapy solutions, Creative Biolabs has developed a range of customized services centered on iPSC-derived macrophages. These services provide comprehensive support for research into immunotherapy and the treatment of genetic disorders, including:

* iPSC to macrophage differentiation

* Functional analysis of iPSC-derived macrophages

* Transcriptome analysis

* Polarization assays

* Disease modeling

"Through the use of macrophage polarization models, our researchers can analyze the functions of macrophages in various diseases, offering a powerful tool for the exploration of novel therapies," the spokesperson continued. Additionally, Creative Biolabs' iPSC-derived macrophage polarization assays allow for in-depth study of macrophage roles in disease progression.

Creative Biolabs has successfully introduced macrophage lines from multiple species and sources, including M0, M1, and M2 macrophages from humans, canines, and hamsters. Their portfolio also includes high-quality human M0 macrophages, ideal for polarization studies.

"These human macrophages can be polarized into M1 or M2 phenotypes under specific conditions, making them invaluable for studying the unique roles of each macrophage type in immune responses," the expert added.

One critical factor in iPSC generation and application is fibroblast growth factor 2 (FGF2), which regulates cell proliferation and self-renewal by binding to fibroblast growth factor receptors. To meet the needs of stem cell researchers, Creative Biolabs has introduced two high-performance FGF2 products:

* Recombinant human FGF2, known for its high bioactivity, is suitable for culturing a wide range of cell types.

* FGF2 STAB, an enhanced version with increased stability through amino acid substitutions, extends its half-life to over seven days. "This product delivers the same bioactivity as regular FGF2 while reducing the need for frequent media changes, saving both time and resources for researchers," the expert concluded.

For more information on Creative Biolabs' iPSC-derived macrophage services and related products, please visit https://www.creative-biolabs.com/stem-cell-therapy.

About Creative Biolabs

Creative Biolabs is dedicated to advancing scientific research through innovative biotechnology solutions. By offering iPSC-derived macrophage technology, customized services, and high-quality products, the company supports researchers worldwide in making breakthroughs in stem cell therapy and immunotherapy. Whether it's for disease modeling, drug screening, or therapeutic development, Creative Biolabs provides cutting-edge technical expertise and solutions.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/stem-cell-therapy



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Copyright © 1995-2016 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.